Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does VALGANCICLOVIR Cause Thrombotic microangiopathy? 98 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 98 reports of Thrombotic microangiopathy have been filed in association with VALGANCICLOVIR (VALGANCICLOVIR). This represents 1.2% of all adverse event reports for VALGANCICLOVIR.

98
Reports of Thrombotic microangiopathy with VALGANCICLOVIR
1.2%
of all VALGANCICLOVIR reports
50
Deaths
65
Hospitalizations

How Dangerous Is Thrombotic microangiopathy From VALGANCICLOVIR?

Of the 98 reports, 50 (51.0%) resulted in death, 65 (66.3%) required hospitalization, and 2 (2.0%) were considered life-threatening.

Is Thrombotic microangiopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for VALGANCICLOVIR. However, 98 reports have been filed with the FAERS database.

What Other Side Effects Does VALGANCICLOVIR Cause?

Off label use (1,882) Cytomegalovirus infection (1,091) Drug ineffective (886) Neutropenia (809) Leukopenia (574) Drug resistance (524) Cytomegalovirus viraemia (447) Pancytopenia (434) Cytomegalovirus infection reactivation (374) Death (359)

What Other Drugs Cause Thrombotic microangiopathy?

TACROLIMUS (1,982) MYCOPHENOLATE MOFETIL (820) CYCLOSPORINE (724) GEMCITABINE (648) ECULIZUMAB (636) CYCLOPHOSPHAMIDE (602) FLUDARABINE (480) METHOTREXATE (447) CARFILZOMIB (350) METHYLPREDNISOLONE (345)

Which VALGANCICLOVIR Alternatives Have Lower Thrombotic microangiopathy Risk?

VALGANCICLOVIR vs VALIUM VALGANCICLOVIR vs VALPROATE VALGANCICLOVIR vs VALPROIC ACID VALGANCICLOVIR vs VALPROMIDE VALGANCICLOVIR vs VALSARTAN

Related Pages

VALGANCICLOVIR Full Profile All Thrombotic microangiopathy Reports All Drugs Causing Thrombotic microangiopathy VALGANCICLOVIR Demographics